GLPwatch
Papers (12034)
Page 42 of 201, ranked by citation count.
- Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
- Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
- Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity.
- Liraglutide alleviates diabetic cardiomyopathy by blocking CHOP-triggered apoptosis via the inhibition of the IRE-α pathway.
- Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway.
- Exendin-4 inhibits glucolipotoxic ER stress in pancreatic β cells via regulation of SREBP1c and C/EBPβ transcription factors.
- MondoA Is an Essential Glucose-Responsive Transcription Factor in Human Pancreatic β-Cells.
- Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro.
- Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
- Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance.
- Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
- Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway.
- Long-Term Activation of Glucagon-like peptide-1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes.
- Improved diastolic function in type 2 diabetes after a six month liraglutide treatment.
- Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients.
- A narrative review of approved and emerging anti-obesity medications.
- Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
- Exendin-4, a GLP-1 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia-reperfusion injury.
- Fluorescent exendin-4 derivatives for pancreatic β-cell analysis.
- The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD.
- Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
- Liraglutide activates autophagy <i>via</i> GLP-1R to improve functional recovery after spinal cord injury.
- GLP-1 agonists in type 1 diabetes.
- The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.
- Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
- Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI).
- Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery.
- Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo.
- Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent.
- Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3.
- Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review.
- Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats.
- GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
- Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
- Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
- Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β.
- Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.
- Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice.
- Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure.
- Therapeutic effect of exendin-4, a long-acting analogue of glucagon-like peptide-1 receptor agonist, on nerve regeneration after the crush nerve injury.
- GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor.
- Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
- Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells.
- Liraglutide, leptin and their combined effects on feeding: additive intake reduction through common intracellular signalling mechanisms.
- Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus.
- Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.
- Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.
- Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats.
- GLP-1 improves adipose tissue glyoxalase activity and capillarization improving insulin sensitivity in type 2 diabetes.
- Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
- The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
- Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis.
- Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
- Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.
- Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
- Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group.
- Liraglutide: a review of its use in the management of obesity.
- Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management.
- Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland.
- Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.